Eton Pharmaceuticals Inc (NASDAQ: ETON) is 327.13% higher on its value in year-to-date trading and has touched a low of $3.22 and a high of $21.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ETON stock was last observed hovering at around $13.96 in the last trading session, with the day’s gains setting it 325.07%.
Currently trading at $339.03K, the stock is -8.17% and -15.32% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.39 million and changing 4387675% at the moment leaves the stock 7.60% off its SMA200. ETON registered 5.18% gain for a year compared to 6-month gain of 12.08%. The firm has a 50-day simple moving average (SMA 50) of $16.544 and a 200-day simple moving average (SMA200) of $13.0201.
The stock witnessed a -30.23% loss in the last 1 month and extending the period to 3 months gives it a 3.70%, and is 3.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.48% over the week and 6.29% over the month.
Eton Pharmaceuticals Inc (ETON) has around 31 employees, a market worth around $375.71M and $48.33M in sales. Fwd P/E is 10.97. Profit margin for the company is -9.49%. Distance from 52-week low is 335.09% and -34.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-8.41%).
The EPS is expected to grow by 402.22% this year.
Eton Pharmaceuticals Inc (ETON) Top Institutional Holders
107.0 institutions hold shares in Eton Pharmaceuticals Inc (ETON), with institutional investors hold 55.49% of the company’s shares. The shares outstanding are 26.82M, and float is at 22.93M with Short Float at 4.89%. Institutions hold 53.06% of the Float.
The top institutional shareholder in the company is OPALEYE MANAGEMENT INC. with over 2.4 million shares valued at $7.88 million. The investor’s holdings represent 9.2963% of the ETON Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.03 million shares valued at $3.38 million to account for 3.989 of the shares outstanding. The other top investors are NANTAHALA CAPITAL MANAGEMENT, LLC which holds 0.94 million shares representing 3.6515% and valued at over $3.1 million, while WESTSIDE INVESTMENT MANAGEMENT, INC. holds 2.2723 of the shares totaling 0.59 million with a market value of $1.93 million.
Eton Pharmaceuticals Inc (ETON) Insider Activity
The most recent transaction is an insider sale by Krempa David, the company’s Chief Business Officer. SEC filings show that Krempa David sold 16,977 shares of the company’s common stock on Jun 12 ’25 at a price of $14.92 per share for a total of $0.25 million. Following the sale, the insider now owns 0.63 million shares.
Eton Pharmaceuticals Inc disclosed in a document filed with the SEC on Jun 16 ’25 that Krempa David (Chief Business Officer) sold a total of 10,223 shares of the company’s common stock. The trade occurred on Jun 16 ’25 and was made at $14.73 per share for $0.15 million. Following the transaction, the insider now directly holds 0.61 million shares of the ETON stock.
Still, SEC filings show that on Jun 13 ’25, Krempa David (Chief Business Officer) disposed off 6,800 shares at an average price of $14.77 for $0.1 million. The insider now directly holds 622,869 shares of Eton Pharmaceuticals Inc (ETON).
